New clinical evidence collected from >65,000 women with breast cancer demonstrates 83% of positive test results are found in genes that impact clinical management Multi-gene germline genetic testing allows for efficient analysis, maximizing risk assessment while minimizing the time needed for results. This has been particularly effective…
The short answer is: Genetic testing is possible, but depends on other factors. The question of whether genetic testing is possible for patients with a history of hematological cancer comes up often in the clinical setting and in the testing laboratory. This makes sense since genetic testing is performed on DNA isolated from white blood cells…
Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome caused by CDH1 gene mutations. It occurs most frequently in Japan and eastern Asia; current incidence in the U.S. is estimated at 10-40 individuals per 100,000.1 Individuals with mutations in the CDH1 gene have up to an 80% lifetime risk of diffuse gastric…
Ambry has continued to provide clinicians with the most relevant and useful information to encourage education about the benefits of genetic testing for patients and ways to streamline genetic testing in clinical practice. At the 2017 SSO Annual Cancer Symposium, Ambry hosted the presentation “On the Cutting Edge: Sharpening Your Genetic Awareness…
On Thursday evening, March 23rd, an audience of more than 100 genetic counselors and geneticists from across the United States listened to Ambry Genetics’ Clinical Genomics Marketing Manager Layla Shahmirzadi, MS, CGC, discuss plans to launch a personalized genomic test for healthy individuals. The talk took place at Events on Jackson venue…
Actionable medical results are often a key component in deciding a patient’s medical management and specialized treatment options. However, some genetic test results can have unclear implications or Variants of Unknown Significance (VUS), which can often affect a clinician’s medical management plans for their patients. During the 2017 ACMG…
Ambry experts and collaborators presented new research at this year’s Annual Meeting on Women’s Cancer. In addition to discussing GYNplus and OvaNext testing options, Ambry featured three scientific posters and a lunch presentation “Advancing Molecular Diagnostics for Gynecologic Cancer: Efforts in Data Sharing and Tumor Testing to Improve…
Colon cancer is the third most common cancer diagnosed in both men and women in the United States, and more than 95,000 new cases of colon cancer and 39,000 new cases of rectal cancer are estimated for 2017, according to the American Cancer Society. Up to 10% of colorectal cancer is hereditary, or caused by inherited gene mutations. Hereditary…
Ribonucleic Acid, otherwise known as RNA, is the messenger that carries instructions for controlling the synthesis of proteins from Deoxyribonucleic Acid (DNA). The central dogma of molecular biology states that “DNA makes RNA makes protein." However, for the proteins, which are the final product, to work properly, the RNA needs to be “edited,"…
Since March 2016, Ambry has been collecting data samples from researchers through the data sharing program AmbryShare, with a goal of improving scientific research aimed at making more tailored treatments and/or cures available to clinicians and their patients. Now anyone can participate in a research study and choose to either submit an e-consent…